Premium
A metagenomic study of the preventive effect of Lactobacillus rhamnosus GG on intestinal polyp formation in Apc Min/+ mice
Author(s) -
Ni Y.,
Wong V.H.Y.,
Tai W.C.S.,
Li J.,
Wong W.Y.,
Lee M.M.L.,
Fong F.L.Y.,
ElNezami H.,
Panagiotou G.
Publication year - 2017
Publication title -
journal of applied microbiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.889
H-Index - 156
eISSN - 1365-2672
pISSN - 1364-5072
DOI - 10.1111/jam.13386
Subject(s) - lactobacillus rhamnosus , metagenomics , probiotic , biology , shotgun sequencing , microbiology and biotechnology , gut flora , lactobacillus , roseburia , bacteria , immunology , biochemistry , genetics , genome , gene
Aims To investigate the in vivo effects of Lactobacillus rhamnosus GG ( LGG ) on intestinal polyp development and the interaction between this single‐organism probiotic and the gut microbiota therein. Methods and Results The Apc Min/+ mouse model was used to study the potential preventive effect of LGG on intestinal polyposis, while shotgun metagenomic sequencing was employed to characterize both taxonomic and functional changes within the gut microbial community. We found that the progression of intestinal polyps in the control group altered the community functional profile remarkably despite small variation in the taxonomic diversity. In comparison, the consumption of LGG helped maintain the overall functional potential and taxonomic profile in the resident microbes, thereby leading to a 25% decrease of total polyp counts. Furthermore, we found that LGG enriched those microbes or microbial activities related to short‐chain fatty acid production (e.g. Roseburia and Coprococcus ), as well as suppressed the ones that can lead to inflammation (e.g. Bilophila wadsworthia ). Conclusions Our study using shotgun metagenomics highlights how single probiotic LGG may exert its beneficial effects and decrease polyp formation in mice by maintaining gut microbial functionality. Significance and Impact of the Study This probiotic intervention targeting microbiota may be used in conjugation with other dietary supplements or drugs as part of prevention strategies for early‐stage colon cancer, after further clinical validations in human.